AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05662462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provider dashboard
Description: The ACHIEVE intervention will include a bi-directional dashboard that displays information about individuals, including priority care goals and pathways, and recommendations generated via PROMPT. Healthcare team members can access the dashboard embedded within a portal to modify or update information and close the loop on participant tasks. The dashboard will present recommendations for participant goals and pathways provided by the PROMPT algorithms. Providers can use these recommendations or manually select ones for the participant. Providers can sequence goals and pathways by level of complexity. Both the HUB and the healthcare team can perform ongoing assessments of HUB pathway selections and assess recurring needs through the provider dashboard.
Study NCT05703516 — intervention group
Intervention type: OTHER
Intervention: Capmatinib
Description: There is no treatment allocation. Capmatinib will be prescribed by the physician as per locally approved label. Treatment duration depends on the decision of treating physician. No drug will be dispensed from Novartis
Study NCT05442866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality experience for 10 minutes
Description: Each 10-minute VR session will be self-administered (by each participant) using the Facebook (Facebook Inc., Menlo Park, CA) Meta Quest 2 VR and Touch controllers. This equipment was selected because it is portable, has built in audio, and has clear graphics at a lower price than VR setups that require a computer to generate graphics. The headset has an optional eyeglass spacer to allow participants to wear corrective eyeglasses during the VR session if appropriate. The hand controllers facilitate immersive, interactive VR experiences. The VR software, Nature Treks VR application (https://naturetreksvr.com) that features ten non-violent, nature-based experiences in peaceful environments (e.g. forest, river, beach, etc.) that can be played in a seated or fixed position.
Study NCT06039982 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04882332 — intervention group
Intervention type: OTHER
Intervention: sampling for diabetes control parameters
Description: Intravenous blood withdrawal for a sample of fasting blood glucose (FBG), 2 hr postprandial blood glucose (2 hr -PPG), fasting lipids {total cholesterol (TC), triglycerides (TAG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)}, glycosylated hemoglobin (Hb A1c) ,fasting insulin level and Vitamin B 12 levels
Study NCT04882332 — intervention group
Intervention type: OTHER
Intervention: Sampling for vitamin B12 level
Description: Intravenous blood sampling for a sample of vitamin B12 level
Study NCT05165056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intimleds
Description: INTIMILEDS® is a photobiomodulation device designed for intravaginal use. It's design permits an irradiation of the whole vaginal wall, the vulva, and the cervix, with a constant intensity.
Study NCT06495905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transbronchoscopic interventional debridement
Description: 1. combination drug therapy：liposomal amphotericin B + posaconazole or Isavuconazole：3-5mg/kg/day+ Posaconazole 300 mg once daily; target blood trough concentration is >1ug/mL; if posaconazole is unavailable, Isavuconazole 200 mg once daily may be an alternative.~2. transbronchoscopic local precision infusion of amphotericin B: Maximum dose not more than 30mg per session~3. transoral nebulized inhalation of amphotericin B：amphotericin B 10mg + 5ml of sterilized water for injection, inhalation 2/day.~4)transbronchoscopic interventional debridement
Study NCT05486637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perception of acoustic cues to emotion
Description: Using novel methodologies and stimuli comprising both controlled laboratory recordings and materials culled from databases of ecologically valid speech emotions (e.g., from publicly available podcasts), the team aims to collect perceptual data to build a statistical model to test the hypothesis that experience-based changes in emotion identification by pediatric and adult CI recipients is mediated by improvements in cue-optimization.
Study NCT05486637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Production of acoustic cues to emotion
Description: The team will acoustically analyze vocal emotion productions by participants, quantify acoustic features of spoken emotions, and obtain behavioral measures of how well normally hearing listeners can identify those emotions.
Study NCT04796961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation Intervention
Description: The implementation intervention involves training, coaching, expert consultation, organizational strategy meetings.
Study NCT05470803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca/Fiocruz
Description: 4th dose of SARS-CoV-2 vaccine
Study NCT05470803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer/Wyeth
Description: 4th dose of SARS-CoV-2 vaccine
Study NCT05470803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clover SCB-2019
Description: 4th dose of SARS-CoV-2 vaccine
Study NCT04785456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TBS
Description: MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
Study NCT04785456 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS
Description: MagPro X100 device equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark)
Study NCT05039190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HBM9161 Injection (680mg)
Description: HBM9161 Injection
Study NCT05039190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Injection
Study NCT04272515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: collection of blood sample for preparation of DNA
Study NCT04272515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy sampling
Description: preparation of primary cultures of dermal fibroblasts from skin biopsy sample
Study NCT04272515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: explanted liver of BA patients sampling
Description: cryoconservation of liver tissue for molecular analyses
Study NCT05037110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: For 12 weeks, do 150 minutes of moderate physical activity per week and wear a smart watch to monitor this physical activity goal. This is done remotely. Then, every two weeks, attend a remote individual meeting with a kinesiologist using a secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of health and activities recorded by the activity watch/app provided to the participant; 2) Discussion on how to reach/maintain the physical activity goal in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
Study NCT05037110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell training
Description: For 12 weeks, morning and evening, smell four odors namely eucalyptol, phenyl ethanol, citronellal, and eugenol, for a total of five minutes per session. For each smell training session, complete a short, online survey regarding the pleasantness and intensity of the smell. This is done remotely. Then, every two weeks, attend a remote individual meeting with a research professional using secured application (15 minutes each). Each online meeting will contain the following steps: 1) Review of smell training; 2) Discussion on how to reach/maintain the training protocol in the coming weeks according to individual health status, facilitators and barriers; 3) Elaboration of the next 2-week action plan.
Study NCT06195020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metaverse
Description: The research consists of two stages (preparation and implementation). In the first stage of the research, the educational material planned to be used in the education of parents (video of navigation in the metaverse) will be developed in the form of modules. The topics in the training materials to be developed are listed below.~Module 1: Information about Epilepsy (What is epilepsy?, What are the causes of epilepsy? Module 2 Diagnostic Methods in Epilepsy (Neurological examination, blood tests, electroencephalogram, screening tests 3rd Module Treatment of Epilepsy (Things to consider in patients receiving antiepileptic drug therapy) Module 4: First Aid in Epilepsy (first aid in seizures with convulsions, first aid in seizures without convulsions) Module 5: Life with Epilepsy (Epilepsy and school, epilepsy and career choice, epilepsy and home safety, epilepsy and exercise, epilepsy and healthy nutrition, epilepsy and sleep) The intervention will last 3 months.
Study NCT06195020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polyclinic information
Description: This group will be informed only at the outpatient clinic. The intervention will last 3 months.
Study NCT04743557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYN101
Description: DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
Study NCT05086445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally
Study NCT05086445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05872087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised Dexmeditomidine
Description: premedication by dexmeditomidine 3mcg/kg in children undergoing lower abdominal surgeries
Study NCT05872087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulised Midazolam
Description: premedication by nebulised midazolam 0.3mg/kg in children undergoing lower abdominal surgeries
Study NCT06403085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study group
Description: Rhythmic Stabilization, Limb Matching, Double and Single Arm Balance, Balance with Ball and Weight Transfer will be performed for 8 weeks.
Study NCT06300853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses
Description: Whole blood and serum samples will be longitudinally collected at the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1). Possible further time points will be collected within 2 years, based on the National recommended future vaccination regimens.~Biological samples will be used for the following exams:~* Cellular immunity characterization~  * T- and B-cells Immunophenotype.~ * Specific T-cell response.~ * In vitro specific B-cells characterization.~ * Antibody-dependent cellular cytotoxicity.~* Humoral response characterization~  * Serology assays.~ * Avidity assay.~ * Neutralization assays with different SARS-CoV-2 variants.~ * Presence of specific or cross-reactive antibodies for common hCoV.~* Genetic and epigenetic analysis
Study NCT05824429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urotherapy
Description: Urotherapy is an umbrella term that includes components such as information about bladder function and problem, lifestyle changes including the regulation of voiding and fluid intake times, correct toilet positions, information about bladder irritants, and motivation. All participants included in our study will be given urotherapy training before starting PFM exercises and CTM with their families.
Study NCT05824429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: Urotherapy is an umbrella term that includes components such as information about bladder function and problem, lifestyle changes including the regulation of voiding and fluid intake times, correct toilet positions, information about bladder irritants, and motivation. All participants included in our study will be given urotherapy training before starting PFM exercises and CTM with their families.
Study NCT05824429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercises
Description: In our research, diaphragm breathing exercises will be applied to both groups before starting PFM exercises in sessions for 8 weeks, 3 days a week.
Study NCT05824429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic Breathing Exercises
Description: In our research, diaphragm breathing exercises will be applied to both groups before starting PFM exercises in sessions for 8 weeks, 3 days a week.
Study NCT05824429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFM Exercises
Description: PFM exercises will be started after children learn to contract and relax their PFM in isolation without the use of auxiliary muscles. In the exercises, fast and slow contractions targeting type 1 and type 2 muscle fibers will be taught to increase both strength and endurance of PFM.
Study NCT05824429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFM Exercises
Description: PFM exercises will be started after children learn to contract and relax their PFM in isolation without the use of auxiliary muscles. In the exercises, fast and slow contractions targeting type 1 and type 2 muscle fibers will be taught to increase both strength and endurance of PFM.
Study NCT05824429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation
Description: CTM is a reflex treatment technique that is applied manually by physiotherapists to the skin area and acts on some cells and connective tissue by making short and long pulls (. In our study, CTM will be applied to our study group, where CTM and PFMR will be applied together, 3 days a week, for a total of 8 weeks.~The application will be made to the basic region (sacral), lower thoracic, abdominal and anterior pelvic region.
Study NCT06485154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir
Description: Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, a combination of dolutegravir (integrase strand transfer inhibitor \[INSTI\]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside reverse transcriptase inhibitors), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg
Study NCT06549387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal cross linking
Description: Applying UVA irradiation to the cornea after soaking with riboflavin
Study NCT06205186 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Army Health
Description: A whole health mobile application for Soldiers
Study NCT06327061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Network overdose prevention
Description: Participants are taught overdose prevention methods with network members.
Study NCT06327061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care health education
Description: Participants will receive the standard of care for overdose prevention.
Study NCT06436417 — intervention group
Intervention type: DEVICE
Intervention: Analgesia Nociception Index (ANI) Monitor
Description: Non-invasive monitoring of HRV to evaluate autonomic nervous system activity using the indices of Energy (SDNN) and ANI (HFnu).
Study NCT06436417 — intervention group
Intervention type: BEHAVIORAL
Intervention: Trimodal Prehabilitation
Description: Program of physical exercise, nutritional supplementation, and psychological support according to the RICA guidelines of the Spanish Group for Multimodal Rehabilitation.
Study NCT06232343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parachute Resistance Training
Description: The training programmed duration is of four weeks.The groups will follow the training programmed three times a week. The daily schedule (training group) included four repetitions of maximum intensity 30 m \& 50 m dashes (4 × 30 m, 4 × 50 m). The duration of recovery time between the 30 m \& 50 m runs will be 4 and 6 minutes respectively. Between the last 30 m dash and the first 50 m dash, a 10-minute recovery will be applied. Moreover, sprint speed training should not exceed 400-500 meters in total . To this end, the training programmed of the present study consisted of 4x30m and 4x50m runs, at a frequency of 3 times a week.
Study NCT06232343 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sprinters
Description: control group perform sprinters without any external resistance training for four weeks.
Study NCT06163859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: FCHVs will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. FCHVs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'.
Study NCT05946733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: After induction of general anesthesia, oblique subcostal TAP blocks will be done(14) under the guidance of Sonosite ,superficial probe ,14-15 MHz ultrasound transducer
Study NCT05946733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B
Description: After induction of general anesthesia, bilateral lateral TAP block will be performed (15) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz)
Study NCT05946733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group C
Description: the analgesia will be maintained using a morphine patient-controlled analgesia (PCA) device set to give 1.5 mg bolus administration of morphine without a basic rate and 15 min lock-out time. The total amount of morphine administration will be recorded for the subsequent 24 h
Study NCT06485505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISOtretinoin 10 MG
Description: Low dose isotretinoin as an adjuvant for itraconazole in treating onychomycosis
Study NCT06485505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: excimer light
Description: excimer light as an adjuvant for itraconazole in treating onychomycosis
Study NCT06485505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Itraconazole alone
Study NCT06134440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Oral®
Description: All patients will follow low-fiber diet according to ERAS protocol during the study period. Patients assigned to the experimental arm will assume also Impact Oral®, an oral nutritional supplement with immune-nutrients (hyper-proteic formula), manufactured and commercialized by Nestlé Health Science S.p.a. It is a liquid drink packaged in a brick of 237 ml. Patients will assume Impact Oral® for 5 days before surgery and 5 day after surgery.
Study NCT05182606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot study of algorithms implementation package
Description: The Implementation Bundle will include a link to algorithms in the Electronic Health Record, Smartphrases, audited feedback, and instructions.
Study NCT06348342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise
Description: Training for PFME will be given orally and will cover the importance of FME and how to do the exercises, as well as the conditions and frequency of doing the exercises. You will be told that the exercise should be done when the bladder is empty, three times a day (morning, noon and evening) and repeated 10 times in each set. In the first week of exercise, the pelvic floor muscles will be contracted for 3 seconds and relaxed for 3 seconds, and will be increased by 1 second each week. It will be explained that from the 8th week onwards, it will be done by contracting for 10 seconds and relaxing for 10 seconds and will continue. It will be stated that the learning process of pelvic floor muscle exercise may take 6 weeks to 6 months. It will be stated that this exercise should be applied throughout their lives for the sustainability of PFM strength. The training is planned to last approximately 20 minutes. PFME will last for two months. Women in menopause will be given an exercise chart.
Study NCT05091255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: The procedure involves general or peripheral anesthesia and percutaneous treatment under CT control with probes capable of forming ice spheres of up to 3 cm that will be used in sufficient number to treat the neoplasm completely.
Study NCT05107037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3234 capsule
Description: TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor
Study NCT06348342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Exercise
Description: Activating the contraction of the deep core muscles TrA and mutifidus without disrupting breathing forms the basis of core stabilization exercises. To teach the \&#34;abdominal hallowing\&#34; maneuver, which enables the activation of these muscles, patients will be shown a picture of the TrA muscle and asked to contract their lower abdominal muscles while lying on their back in the hook position. During the maneuver, care will be taken to ensure that no movement occurs in the trunk and pelvis and that diaphragmatic breathing continues. After the abdominal hallowing maneuver is taught, the exercises will be progressed gradually. A home exercise program will be given for this. The 7-level exercise program recommended by Hagins et al. will be used as a home exercise program. The movements in this program load more moments on the muscles that stabilize the lumbar spine as the levels progress. The stages of the exercise program are shared in the brochure to be given to the patients.